SYRSSyros Pharmaceuticals, Inc.

Nasdaq syros.com


$ 5.32 $ 0.05 (0.85 %)    

Tuesday, 14-May-2024 11:37:09 EDT
QQQ $ 443.68 $ -1.11 (-0.25 %)
DIA $ 394.35 $ -0.74 (-0.19 %)
SPY $ 521.03 $ -1.15 (-0.22 %)
TLT $ 90.44 $ -0.17 (-0.18 %)
GLD $ 217.26 $ -0.58 (-0.27 %)
$ 5.06
$ 5.28
$ 5.28 x 200
$ 0.00 x 0
$ 5.24 - $ 5.37
$ 2.09 - $ 8.17
91,760
na
197.23M
$ 0.95
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-27-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-02-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-15-2022 12-31-2021 10-K
11 11-05-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-04-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-05-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-01-2019 06-30-2019 10-Q
21 05-01-2019 03-31-2019 10-Q
22 03-07-2019 12-31-2018 10-K
23 11-01-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-12-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 08-09-2017 06-30-2017 10-Q
29 05-15-2017 03-31-2017 10-Q
30 03-20-2017 12-31-2016 10-K
31 11-14-2016 09-30-2016 10-Q
32 08-15-2016 06-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 syros-pharmaceuticals-q1-2024-gaap-eps-010-beats-086-estimate--cash-incl-restricted-cash-8564m

Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of...

 crude-oil-down-over-1-cognyte-software-shares-plummet

U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.4% on Tuesday. The Dow traded down 0...

 why-tilray-brands-shares-are-trading-lower-by-around-22-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter esti...

 piper-sandler-reiterates-overweight-on-syros-pharmaceuticals-maintains-13-price-target

Piper Sandler analyst Edward Tenthoff reiterates Syros Pharmaceuticals (NASDAQ:SYRS) with a Overweight and maintains $13 pri...

 top-3-health-care-stocks-youll-regret-missing-this-month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

 hc-wainwright--co-reiterates-buy-on-syros-pharmaceuticals-maintains-15-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Syros Pharmaceuticals (NASDAQ:SYRS) with a Buy and maintains $15 pric...

 syros-pharmaceuticals-q4-eps-222-misses-114-estimate-sales-38600k-miss-200m-estimate

Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(2.22) per share which missed the analyst consensus estimate ...

 earnings-scheduled-for-march-27-2024

Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on rev...

 syros-announces-completion-of-enrollment-of-190-patients-necessary-to-support-primary-endpoint-analysis-in-select-mds-1-phase-3-trial

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline...

 syros-highlights-anticipated-2024-milestones-for-tamibarotene

-- On-Track to Complete Enrollment of 190 patients for Primary Analysis in SELECT-MDS-1 Phase 3 Trial in 1Q 2024; Pivotal CR ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION